Companies › Kringle Pharma
1 active drug program in 1 registered trial: 1 Phase 3; Respiratory; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KP-100LI Recombinant human hepatocyte growth factor (HGF) | HGF | Phase 3 | Vocal Fold Scar | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05627648 | KP-100LI | Phase 3 | Vocal Fold Scar | Respiratory | Feb 2027 |
Bellus Health Inc. - a GSK company Biotest Areteia Therapeutics PureTech Renovion
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.